January 14, 2009

Celldex Therapeutics Inc. announced that it has agreed to sell its poultry vaccines business to Lohmann Animal Health International.

Celldex president and chief executive officer, Anthony S. Marucci said the company will continue to focus strategically on its Precision Targeted Immunotherapy Platform and the clinical and preclinical programmes that are emerging from this novel approach to immunotherapy.

Marucci added that Celldex is very pleased to have found an appropriate home for its poultry vaccines with Lohmann, as a result of the company's focus on health care.

Lohmann Animal Health International chief executive officer, David Zacek said Megan(R)Vac 1 and Megan(R)Egg will remain important vaccines within its growing poultry products business.

Since 2002, Lohmann has performed all manufacturing, marketing and distribution activities for Celldex's marketed Megan(R)Vac 1 and Megan(R)Egg poultry vaccines and has paid Celldex product royalties.